Hammouda N A, el-Mansoury S T, el-Azzouni M Z, el-Gohari Y
Department of Parasitology, Faculty of Medicine, Alexandria University, Egypt.
J Egypt Soc Parasitol. 1995 Apr;25(1):137-43.
Human fascioliasis is becoming an increasingly important clinical and epidemiological problem in Egypt. However, the treatment of the disease presents certain difficulties as the usual known drugs such as emetine hydrochloride and praziquantel do not cure fascioliasis using a single dose. Recently, ten cases were presented with a variability of clinical manifestations suggesting fascioliasis. The indirect haemagglutination test (IHA) was positive with high eosinophilia. SGOT and SGPT were normal & no signs of heart or kidney diseases. After taking the consent of the patients, triclabendazole, a novel benzimidazole compound was given orally in a single dose of 10mg/kg body weight. The results hereby revealed that the general condition and all signs of the patients were ameliorated with a drop in the eosinophilic count, which returned to normal after 2-3 months. Being safe, reliable and easy to administer, triclabendazole is ought to be considered for the treatment of human fascioliasis.
在埃及，人体肝片吸虫病正成为一个日益重要的临床和流行病学问题。然而，由于常用的已知药物如盐酸依米丁和吡喹酮单剂量无法治愈肝片吸虫病，该病的治疗存在一定困难。最近，有10例患者出现了提示肝片吸虫病的多种临床表现。间接血凝试验（IHA）呈阳性，嗜酸性粒细胞增多。谷草转氨酶（SGOT）和谷丙转氨酶（SGPT）正常，且无心脏或肾脏疾病迹象。在征得患者同意后，给予一种新型苯并咪唑化合物三氯苯达唑，口服单剂量为10mg/kg体重。结果显示，患者的一般状况和所有体征均得到改善，嗜酸性粒细胞计数下降，2 - 3个月后恢复正常。由于三氯苯达唑安全、可靠且易于给药，应考虑将其用于治疗人体肝片吸虫病。
